A2 BIOTHERAPEUTICS, INC.

Profile

Company Names

A2 BIOTHERAPEUTICS, INC.

Addresses

30301 AGOURA ROAD, #210, AGOURA HILLS, CA 91301

Phone Numbers

805-491-1988

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY

Year Incorporated:

2017

State Incorporated:

DELAWARE

Total Amount Raised:

$143,132,204.00

Number of Funding Rounds:

2
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
2
2022-11-04 
$71,605,105.00 
$71,605,105.00 
$0.00 
Equity 
1
2020-09-30 
$71,527,099.00 
$71,527,099.00 
$0.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
SRINI 
 
AKKARAJU 
DIRECTOR
SYNAGEVA BIOPHARMA CORP.   |  SMM SPV I, LLC   |  ATYR PHARMA INC   |  CHINOOK THERAPEUTICS U.S., INC.   |  A2 BIOTHERAPEUTICS, INC.
MADHAVAN 
 
BALACHANDRAN 
DIRECTOR
AMGEN INC   |  CATALENT, INC.   |  ADRX, INC.   |  A2 BIOTHERAPEUTICS, INC.   |  NUTCRACKER THERAPEUTICS, INC.
SCOTT 
 
FORAKER 
EXECUTIVE OFFICER, DIRECTOR
A2 BIOTHERAPEUTICS, INC.
MICHAEL 
 
GALLO 
DIRECTOR
A2 BIOTHERAPEUTICS, INC.
WILLIAM 
 
GO 
EXECUTIVE OFFICER
UNA LUNA VERDE, LP   |  APPARENT ENERGY, INC   |  A2 BIOTHERAPEUTICS, INC.
DAVID 
 
GOEDDEL 
DIRECTOR
IGENICA INC   |  NGM BIOPHARMACEUTICALS INC   |  CONSTELLATION PHARMACEUTICALS INC   |  PELOTON THERAPEUTICS, INC.   |  NURIX, INC.   |  NEURONA THERAPEUTICS INC   |  IGENICA BIOTHERAPEUTICS, INC   |  FLX BIO, INC.   |  EXONICS THERAPEUTICS, INC.   |  SURROZEN, INC.   |  A2 BIOTHERAPEUTICS, INC.   |  HEXAGON BIO INC.   |  COLUMN GROUP V, LP   |  COLUMN GROUP OPPORTUNITY III, LP   |  COLUMN GROUP SPV I, LP   |  NGM BIO HOLDINGS, INC.
ALEXANDER 
 
KAMB 
EXECUTIVE OFFICER, DIRECTOR
A2 BIOTHERAPEUTICS, INC.
C. 
ALEXANDER 
KAMB 
DIRECTOR
A2 BIOTHERAPEUTICS, INC.
SUSAN 
L. 
KELLEY 
DIRECTOR
CERULEAN PHARMA INC.   |  DARE BIOSCIENCE, INC.   |  A2 BIOTHERAPEUTICS, INC.
HELEN 
S. 
KIM 
DIRECTOR
EXICURE, INC.   |  EXICURE, INC.   |  A2 BIOTHERAPEUTICS, INC.   |  ICONOVIR BIO, INC.   |  RECODE THERAPEUTICS, INC.   |  AKTIS ONCOLOGY, INC.
THOMAS 
 
LEUNG 
EXECUTIVE OFFICER
STUDIO6, INC.   |  A2 BIOTHERAPEUTICS, INC.
JAKOB 
 
LOVEN 
DIRECTOR
ARVINAS HOLDING COMPANY, LLC   |  VIVIDION THERAPEUTICS, INC.   |  ARRAKIS THERAPEUTICS, INC.   |  ARVINAS, INC.   |  A2 BIOTHERAPEUTICS, INC.   |  ICONOVIR BIO, INC.   |  HEXAGON BIO INC.
DAVID 
 
LUCAS 
EXECUTIVE OFFICER
FINEMARK HOLDINGS, INC.   |  A2 BIOTHERAPEUTICS, INC.   |  PERCIPIO HEALTH, INC.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2022-12-16
D/A
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2022-11-04 
2022-11-17
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2022-11-04 
2020-10-26
D/A
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2020-09-30 
2020-10-20
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2020-09-30 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#